Security record · archived quarter
CTMX
CytomX Therapeutics, Inc. · Healthcare · Biotechnology
11Tracked holders
0Δ holders
36.17MShares held
$82.10MReported value
+0New positions
−0Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +24.6% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | +11 | 136.41M | $511.64M | +18 | −7 |
| Q1 2026 | 64 | +15 | 111.19M | $522.57M | +20 | −5 |
| Q4 2025 | 49 | -1 | 71.30M | $303.77M | — | −1 |
| Q3 2025 | 14 | 0 | 41.38M | $131.99M | — | — |
| Q2 2025 | 11 | 0 | 36.17M | $82.10M | — | — |
| Q1 2025 | 8 | +1 | 8.01M | $5.09M | +1 | — |
| Q4 2024 | 7 | 0 | 9.00M | $9.27M | +1 | −1 |
| Q3 2024 | 6 | 0 | 8.17M | $9.64M | — | — |
| Q2 2024 | 6 | — | 7.95M | $9.70M | — | — |
Who holds it · Q2 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 9.38M | — | $21.29M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passive) | 9.38M | — | $21.29M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Fidelity (FMR) ✦ | 9.24M | — | $20.97M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Fidelity (FMR) ✦ | 9.24M | — | $20.97M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Fidelity (FMR) ✦ | 9.24M | — | $20.97M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 8.08M | +205.1% | $18.35M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | BlackRock ✦ (passive) | 2.39M | — | $5.42M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 2.39M | — | $5.42M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passive) | 2.39M | — | $5.42M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (passive) | 2.39M | — | $5.42M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 2.35M | +2650.9% | $5.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Marshall Wace ✦ | 2.35M | +2650.9% | $5.34M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 1.86M | +61.1% | $4.23M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | Geode Capital Management ✦ (passive) | 1.75M | +103.4% | $3.96M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 15 | Geode Capital Management ✦ (passive) | 1.75M | +103.4% | $3.96M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 16 | State Street Global Advisors ✦ (passive) | 639.04K | +99.7% | $1.45M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 17 | Millennium Management ✦ | 233.34K | -91.7% | $529,680 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 157.68K | +35.4% | $357,936 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 85.51K | +85409.0% | $194,105 | 0.0% | ▲ Add | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 178 holders, 193.14M shares, $906.86M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2025 ·
Methodology ·
Get this via the API